The Zhitong Finance App learned that Bambusa Therapeutics, a biotech company focused on immunology and inflammation, announced the terms of its initial public offering (IPO) on Monday. The company plans to raise $150 million by issuing 9.4 million shares in the price range of $15 to $17 per share. Based on the median value of the proposed offering price range, Bambusa Therapeutics' fully diluted market value would reach $837 million. The company plans to list on NASDAQ under the ticker symbol “BBTX.” The IPO is expected to be priced in the week of October 26, 2026
Bambusa Therapeutics, headquartered in Boston, Massachusetts, USA, is a clinical-stage biotech company developing long-lasting bispecific antibodies for immunology and inflammatory diseases. Its core drug candidate BBT001 targets IL-4Rα and IL-31. It is currently undergoing phase I trials for atopic dermatitis, and preliminary proof of concept data was published in July 2026; at the same time, the drug is also undergoing phase IIa trials for chronic spontaneous urticaria in China.
The company's second drug candidate, BBT002, targets IL-4Rα and IL-5, and is currently undergoing phase I to IIa trials for chronic obstructive pulmonary disease (COPD), chronic sinusitis with nasal polyps, and asthma.
In addition, the company also has two preclinical projects: BBT003 targets TL1a and IL-23p19 to treat inflammatory bowel disease; BBT004 is a bispecific antibody used to treat autoimmune diseases and can deplete B cells. Bambusa Therapeutics' core assets are all authorized by the Chinese subsidiary of German biotech company BioNTech.